(Q35175957)

6 August 2017

title

Pathologic features the urologist should expect on a prostate biopsy (English)

1 reference

6 August 2017

Mingxin Che

1

1 reference

6 August 2017

Wael Sakr

series ordinal

2

1 reference

6 August 2017

David Grignon

series ordinal

3

1 reference

6 August 2017

publication date

1 March 2003

1 reference

6 August 2017

1 reference

6 August 2017

volume

21

1 reference

6 August 2017

issue

2

1 reference

6 August 2017

page(s)

153-161

1 reference

Results of conservative management of clinically localized prostate cancer.

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900008-5

7 January 2021

Correlation of pathologic findings with progression after radical retropubic prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900008-5

7 January 2021

Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900008-5

7 January 2021

Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900008-5

7 January 2021

Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900008-5

7 January 2021

Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900008-5

7 January 2021

Prostate cancer: transrectal ultrasound and pathology comparison. A preliminary study of outer gland (peripheral and central zones) and inner gland (transition zone) cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900008-5

7 January 2021

Disease progression following radical prostatectomy in men with Gleason score 7 tumor

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900008-5

7 January 2021

Should Gleason score 7 prostate cancer be considered a unique grade category?

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900008-5

7 January 2021

Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900008-5

7 January 2021

Gleason score 7 prostate cancer: a heterogeneous entity? Correlation with pathologic parameters and disease-free survival

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900008-5

7 January 2021

Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900008-5

7 January 2021

Percent of cancer in the biopsy set predicts pathological findings after prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900008-5

7 January 2021

Clinical utility of percent prostate needle biopsy tissue with cancer cutpoints to risk stratify patients before radical prostatectomy.

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900008-5

7 January 2021

Predicting disease recurrence in intermediate and high-risk patients undergoing radical prostatectomy using percent positive biopsies: results from CaPSURE.

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900008-5

7 January 2021

Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900008-5

7 January 2021

Preoperative parameters for predicting early prostate cancer recurrence after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900008-5

7 January 2021

Perineural invasion and MIB-1 positivity in addition to Gleason score are significant preoperative predictors of progression after radical retropubic prostatectomy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900008-5

7 January 2021

Evidence of increased failure in the treatment of prostate carcinoma patients who have perineural invasion treated with three-dimensional conformal radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900008-5

7 January 2021

Influence of biopsy perineural invasion on long-term biochemical disease-free survival after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900008-5

7 January 2021

Seminal vesicle biopsy in prostate cancer staging

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900008-5

7 January 2021

Seminal vesicle biopsy and laparoscopic pelvic lymph node dissection: Implications for patient selection in the radiotherapeutic management of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900008-5

7 January 2021

Indications for Seminal Vesicle Biopsy and Laparoscopic Pelvic Lymph Node Dissection in Men With Localized Carcinoma of Prostate

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900008-5

7 January 2021

Should a Gleason score be assigned to a minute focus of carcinoma on prostate biopsy?

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900008-5

7 January 2021

Usefulness of immunoperoxidase staining with high-molecular-weight cytokeratin in the differential diagnosis of small-acinar lesions of the prostate gland

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900008-5

7 January 2021

The utility of basal cell-specific anti-cytokeratin antibody (34 beta E12) in the diagnosis of prostate cancer. A review of 228 cases.

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900008-5

7 January 2021

Comparison of the basal cell-specific markers, 34betaE12 and p63, in the diagnosis of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900008-5

7 January 2021

p63 protein expression is rare in prostate adenocarcinoma: implications for cancer diagnosis and carcinogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900008-5

7 January 2021

p63 is a prostate basal cell marker and is required for prostate development

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900008-5

7 January 2021

Biopsy Gleason score: how does it correlate with the final pathological diagnosis in prostate cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900008-5

7 January 2021

How accurately does prostate biopsy Gleason score predict pathologic findings and disease free survival?

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900008-5

7 January 2021

Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900008-5

7 January 2021

Prostate. Practice parameters, pathologic staging, and handling radical prostatectomy specimens

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900008-5

7 January 2021

Discrepancies between Gleason scores of needle biopsy and radical prostatectomy specimens

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900008-5

7 January 2021

Gleason histologic grading of prostatic carcinoma. Correlations between biopsy and prostatectomy specimens

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900008-5

7 January 2021

Significance of small foci of Gleason score 7 or greater prostate cancer on needle biopsy

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900008-5

7 January 2021

Incidence and clinical significance of false-negative sextant prostate biopsies.

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900008-5

7 January 2021

The association of selected pathological features with prostate cancer in a single-needle biopsy accession

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900008-5

7 January 2021

The American cancer society national prostate cancer detection project. Findings on the detection of early prostate cancer in 2425 men

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900008-5

7 January 2021

Observations on pathology trends in 62,537 prostate biopsies obtained from urology private practices in the United States.

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900008-5

7 January 2021

Incidence of high-grade prostatic intraepithelial neoplasia in sextant needle biopsy specimens

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900008-5

7 January 2021

Analysis of repeated biopsy results within 1 year after a noncancer diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900008-5

7 January 2021

Predicting cancer following a diagnosis of high-grade prostatic intraepithelial neoplasia on needle biopsy: data on men with more than one follow-up biopsy

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900008-5

7 January 2021

Architectural patterns of high-grade prostatic intraepithelial neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900008-5

7 January 2021

Atypical adenomatous hyperplasia of the prostate: morphologic criteria for its distinction from well-differentiated carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900008-5

7 January 2021

Prostate cancer diagnosed after initial biopsy with atypical small acinar proliferation suspicious for malignancy is similar to cancer found on initial biopsy

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900008-5

7 January 2021

The focus of "atypical glands, suspicious for malignancy" in prostatic needle biopsy specimens: incidence, histologic features, and clinical follow-up of cases diagnosed in a community practice

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900008-5

7 January 2021

Diagnosis of "suspicious for malignancy" in prostate biopsies: predictive value for cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900008-5

7 January 2021

Follow-up of atypical prostate needle biopsies suspicious for cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900008-5

7 January 2021

High-grade prostatic intraepithelial neoplasia with adjacent atypia is associated with a higher incidence of cancer on subsequent needle biopsy than high-grade prostatic intraepithelial neoplasia alone

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900008-5

7 January 2021

High-grade prostatic intraepithelial neoplasia with adjacent small atypical glands on prostate biopsy

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900008-5

7 January 2021

Strategy for repeat biopsy in patients with high grade prostatic intraepithelial neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900008-5

7 January 2021

Repeat biopsy strategies for men with atypical diagnoses on initial prostate needle biopsy

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900008-5

7 January 2021

Is repeat prostate biopsy for high-grade prostatic intraepithelial neoplasia necessary after routine 12-core sampling?

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900008-5

7 January 2021

Predictors of cancer in repeat extended multisite prostate biopsy in men with previous negative extended multisite biopsy

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900008-5

7 January 2021

Percentage of positive biopsy cores as predictor of clinical outcome in prostate cancer treated with radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900008-5

7 January 2021

10.1016/S1078-1439(03)00008-5

Identifiers

DOI

1 reference

6 August 2017

1 reference